patronestaff-shutterstock-com
patronestaff / Shutterstock.com
17 December 2015PharmaAshley Roughton

Divide and destroy: an overview of poisonous divisionals

A patent application can in effect destroy itself. It works like this: a priority filing might claim a kinase which has an acceptable homology with a particular sequence listing—call that kinase-SL. The filing which is eventually made claims the kinase as originally claimed and a more general description of it, such as any kinase which has general binding characteristics for a class of proteins, of which kinase-SL is a member—call that the class of kinases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
14 July 2026   An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.
Pharma
7 July 2026   Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.
Pharma
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.